Toxic Nephropathies

Maher, John F.

doi:10.1007/978-1-4613-0689-4_39

Therapy of Renal Diseases and Related Disorders 1991

DOI: 10.1007/978-1-4613-0689-4_39

|View full text |Cite

Toxic Nephropathies

John F. Maher¹

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2006

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 216 publications

(182 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

Drug-associated renal dysfunction and injury

2006

View full text Add to dashboard Cite

Renal dysfunction and injury secondary to medications are common, and can present as subtle injury and/or overt renal failure. Some drugs perturb renal perfusion and induce loss of filtration capacity. Others directly injure vascular, tubular, glomerular and interstitial cells, such that specific loss of renal function leads to clinical findings, including microangiopathy, Fanconi syndrome, acute tubular necrosis, acute interstitial nephritis, nephrotic syndrome, obstruction, nephrogenic diabetes insipidus, electrolyte abnormalities and chronic renal failure. Understanding the mechanisms involved, and recognizing the clinical presentations of renal dysfunction arising from use of commonly prescribed medications, are important if injury is to be detected early and prevented. This article reviews the clinical features and basic processes underlying renal injury related to the use of common drugs.

show abstract

Drug-associated renal dysfunction and injury

2006

View full text Add to dashboard Cite

show abstract

Safety Assessment of Ayurvedic Gold Medication Suvarna Bhasma, in Wistar Rats

Kulkarni,

Mohan,

Patil

et al. 2024

IND. DRU.

View full text Add to dashboard Cite

Suvarna bhasma (SB) contains gold and lead, which are highly potent metals and are toxic in their crude form. This study evaluated the safety profile of the medication. Suvarna bhasma was administered for 90 consecutive days orally at three doses (10.23 mg kg-1, 40.92 mg kg-1 and 102.3 mg kg-1 body weight) to wistar rats. Clinical observations, feed and water consumption, and body weight changes were noted during the study period. On the 91st day, hematological, biochemical and histopathological changes were studied. There was a significant decrease in body weight of rats at a low dose (10.23 mg kg-1) at fourth week, which could not be correlated with feed and water consumption findings. Thus, change was not considered as a treatment-related effect. Suvarna bhasma showed no evident untoward effect in haematological, biochemical and histopathological parameters in the 90 day-subchronic toxicity study (OECD 408 guidelines) and was safe in Wistar rats.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Toxic Nephropathies

Cited by 2 publications

References 216 publications

Drug-associated renal dysfunction and injury

Drug-associated renal dysfunction and injury

Safety Assessment of Ayurvedic Gold Medication Suvarna Bhasma, in Wistar Rats

Contact Info

Product

Resources

About